Quarterly Activities/ Appendix 4C Cash Flow Report

Amplia Therapeutics has today released its quarterly report for the period ending 31 December 2025, marking significant advancements across the Company’s clinical, commercial and regulatory programs.  

Key Highlights from the Quarter include: 

• ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate that narmafotinib is well tolerated by patients whilst enhancing the effects of chemotherapy 

• AMPLICITY Trial Initiation: The Phase 1b/2a AMPLICITY trial has started, combining narmafotinib with FOLFIRINOX chemotherapy, aiming to determine the optimal daily dose. Patient recruitment is ongoing in Melbourne and Sydney with US sites planned to open imminently 

• Regulatory and Commercial Developments: Positive FDA feedback on dose optimization was received; a key patent for narmafotinib was granted; and Amplia successfully uplisted to the USbased OTCQB Venture Market, enhancing its investor reach

• Preclinical Studies: The second phase of a research program evaluating the activity of narmafotinib in patient-derived pancreatic cancer cells carrying specific genetic mutations has been initiated 

Looking ahead, mature data is expected from the ACCENT trial, whilst progress with the AMPLICITY trial will also be announced. Additional preclinical data will also be disclosed demonstrating new opportunities for narmafotinib in the treatment of pancreatic and other cancers. 

Read the ASX release